- Autolus Therapeutics ( NASDAQ: AUTL ) said Moderna ( NASDAQ: MRNA ) exercised an option to license AUTL's proprietary binders against an undisclosed immuno-oncology target to develop and commercialize mRNA therapeutics.
- Autolus ( AUTL ) received an option exercise fee, with potential for development milestone payments plus royalties, the company said in an Oct. 12 press release.
- The transaction follows an original August 2021 agreement between the two companies, granting Moderna an exclusive option to license Autolus' binders for up to four immuno-oncology targets for use in certain mRNA therapeutics.
- AUTL +4.03% to $3.10 premarket Oct. 12
For further details see:
Autolus stock rises as Moderna uses option to license targeting technology for mRNA therapy